Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.8110
+0.0260 (3.31%)
May 2, 2025, 10:44 AM EDT - Market open
Kairos Pharma Employees
As of December 31, 2024, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$650,750
Market Cap
13.54M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
KAPA News
- 4 days ago - Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
- 8 days ago - Kairos Pharma Ltd. Provides Letter to Stockholders - Business Wire
- 15 days ago - Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer - Business Wire
- 4 weeks ago - Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer - Business Wire
- 5 weeks ago - Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events - Business Wire
- 6 weeks ago - Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma - Business Wire
- 2 months ago - Kairos Pharma Announces New Department of Defense Funding for Research of ENV205 - Business Wire